PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
On May 12, 2017, PhaseRx, Inc. issued a press release announcing
its financial results for the quarter ended March 31, 2017. A
copy of this press release is furnished as Exhibit 99.1 hereto
and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K (including Exhibit
99.1) is being furnished to Item 2.02 and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise be subject
to the liabilities of that section, and such information shall
not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof and regardless of any
general incorporation language in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Press release, dated May 12, 2017 |
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle. PhaseRx, Inc. (NASDAQ:PZRX) Recent Trading Information
PhaseRx, Inc. (NASDAQ:PZRX) closed its last trading session down -0.02 at 1.24 with 74,880 shares trading hands.